Lenceliv 10mg uses are the following conditions:

• Certain types of advanced thyroid cancer
• Advanced Liver cancer
• Certain types of kidney cancer
• Endometrial cancer

Lenceliv 10mg Capsule blocks the enzyme receptor tyrosine kinases (RTKs). RTKs develop new blood vessels that supply oxygen and nutrients to the cells and help them grow. This medicine inhibits the receptors that facilitate the growth of blood vessels in tumor cells. RTKs are present in high concentrations in cancer cells, and administration of this medicine slows down the rate of cancer cells’ growth and multiplication.

Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Lenceliv 10mg Capsule and reduce effectiveness by causing undesirable side effects. 

• Lenceliv 10mg Capsule should be stored at room temperature, between 20°C to 25°C (68°F to 77°F).
• Protected from light.
• Keep it in its original packaging until it is ready to be used.

Lenceliv 10mg Capsule is an oral medication that is usually taken once a day, at approximately the same time each day, with or without food. It should be taken as prescribed by a doctor or other healthcare provider. These capsules should be swallowed whole with a glass of water. They should not be crushed, chewed, or opened, as this can affect the way the medication is absorbed and decrease its effectiveness. You should not take a double dose to make up the second dose.

Like all medications, Lenceliv 10mg Capsule can cause side effects, although not everyone who takes it will experience them. Lenceliv 10 Capsule Side Effects include

Serious

• Feeling numb or weak on 1 side of the body
• Severe headache
• Fever
• Confusion
• Difficulty speaking
• Vision changes
• Dizziness
• Chest pain or pressure
• Pain in arms, jaw, neck, back
• Breathing problems
• Severe stomach pain
• Blood clot formation
• Blood in stools or coughing blood
• Liver problems
• Pain or soreness in mouth, teeth or jaw
   

Common

• High or low BP
• Loss of appetite
• Nausea, vomiting, constipation, diarrhea or indigestion
• Tiredness
• Hoarse voice
• Leg swelling
• Rashes
• Pain in joints or muscles
• Hair loss
• Sleeplessness
• Protein in urine, frequent urination
• Low potassium, magnesium and calcium levels in the blood
• Dehydration
• Skin problems
• Gall bladder inflammation
• Increase in the values of cholesterol, thyroid-stimulating hormone, digestive enzymes
• Delayed wound healing

• tay in close communication with your healthcare provider and report any concerns or side effects promptly.

• Avoid pregnancy and breastfeeding during treatment.

• Use effective contraception while taking Lenceliv 10mg Capsule and for at least two weeks after stopping treatment.

• Avoid eating grapefruits as they affect the absorption of the medication.

• Use sunscreen and wear protective clothing when outdoors to reduce the risk of sunburn or skin damage.

• Avoid strenuous activities or exercise until you understand how the medication is affecting you.

• Maintain a healthy and balanced diet during treatment to support your overall health and well-being.

• Being informed and engaged in your treatment helps ensure the best outcomes and manage potential risks.

1. Eisai Europe Limited, Electronic Medicines Compendium (EMC), [Revised on Mar 2021] [Accessed on 20th April 2023], https://www.medicines.org.uk/emc/files/pil.6840.pdf
2. Suyama and Iwase, Lenvatinib: A promising molecular targeted agent for multiple cancers, Cancer Control, 2018, 25, 1-5, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056795/pdf/10/1177 1073274818789361.pdf
3. Q.M. Anstee, D.E.J. Jones, Liver and Biliary Tract Disease, Davidson’s Principles and Practice of Medicine, 22nd Edition, 2014, 921-988.
4. M.W.J. Strachan, J. Newell-Price, Endocrine disease, Davidson’s Principles & Practice of Medicine, 22nd Edition, 2014, 733-796.
5. Eisai Inc U.S Food and Safety Drug Administration (FDA) [Last revised Aug 2018], [Accessed on 20th April 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206947s007lbl.pdf